

## East Bridgewater

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	10.9	46.0	(14.8-107.3)	Male	5	6.3	80.0	(25.8-186.7)
Female	2	4.0	nc	(nc-nc)	Female	11	5.2	209.6	(104.5-375.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	2.5	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	52	48.1	108.1	(80.7-141.8)	Female	4	5.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	2.4	nc	(nc-nc)	Male	9	4.8	186.4	(85.1-353.9)
Colon / Rectum					Female	3	2.2	nc	(nc-nc)
Male	26	17.1	151.8	(99.1-222.4)	Ovary				
Female	20	16.1	124.1	(75.8-191.7)	Female	6	4.8	124.3	(45.4-270.6)
Esophagus					Pancreas				
Male	6	2.8	211.7	(77.3-460.7)	Male	1	3.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	3.3	151.2	(48.7-352.7)
Hodgkin Lymphoma					Prostate				
Male	1	1.2	nc	(nc-nc)	Male	56	47.5	118.0	(89.1-153.2)
Female	2	1.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	2	4.8	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Larynx					Testis				
Male	2	2.2	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)

Leukemia	Female	3	0.6	nc	(nc-nc)
	Male	1	3.7	nc	(nc-nc)
	Female	2	3.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	2	2.2	nc	(nc-nc)
	Female	1	0.8	nc	(nc-nc)
Lung and Bronchus	Male	30	21.9	136.8	(92.3-195.3)
	Female	17	19.1	89.0	(51.8-142.6)

#### Thyroid

	Male	1	1.3	nc	(nc-nc)
	Female	6	4.3	138.2	(50.5-300.9)
Uteri Corpus and Uterus, NOS	Female	8	9.4	85.2	(36.7-167.9)
All Sites / Types	Male	167	155.5	107.4	(91.7-125.0)
	Female	170	148.8	114.2	(97.7-132.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

95

#### East Brookfield

##### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	2.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Breast				
Male	1	0.1	nc	(nc-nc)
Female	10	8.6	116.7	(55.9-214.6)
Cervix Uteri				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	1.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)
Oral Cavity & Pharynx				

Colon / Rectum	Female	0	0.4	nc	(nc-nc)	Ovary	Male	0	1.0	nc	(nc-nc)
	Male	2	3.8	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Esophagus	Female	4	3.2	nc	(nc-nc)	Pancreas	Female	1	0.9	nc	(nc-nc)
	Male	1	0.6	nc	(nc-nc)		Male	2	0.7	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.2	nc	(nc-nc)	Prostate	Female	0	0.7	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)		Male	9	10.0	89.8	(41.0-170.5)
Kidney & Renal Pelvis	Male	2	1.0	nc	(nc-nc)	Stomach	Male	2	0.6	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)		Female	1	0.3	nc	(nc-nc)
Larynx	Male	0	0.4	nc	(nc-nc)	Testis	Male	0	0.3	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Leukemia	Male	0	0.8	nc	(nc-nc)	Thyroid	Male	0	0.2	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)		Female	0	0.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.5	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Female	1	1.7	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Male	31	32.8	94.4	(64.1-134.0)
Lung and Bronchus	Male	6	4.8	125.3	(45.7-272.7)	All Sites / Types	Female	27	27.4	98.7	(65.0-143.6)
	Female	3	3.7	nc	(nc-nc)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

96

East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	15	18.7	80.3	(44.9-132.4)	Male	16	9.0	177.3	(101.3-287.9)
Female	8	7.3	109.5	(47.2-215.8)	Female	7	7.1	98.2	(39.3-202.2)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	3.3	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	9	9.0	100.0	(45.6-189.9)
Female	86	70.9	121.3	(97.0-149.8)	Female	14	8.7	160.0	(87.4-268.5)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	3.0	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
Colon / Rectum					Female	6	3.5	172.2	(62.9-374.9)
Male	14	28.6	48.9	(26.7-82.1)	Ovary				
Female	24	30.2	79.4	(50.9-118.2)	Female	6	7.3	82.4	(30.1-179.3)
Esophagus					Pancreas				
Male	1	4.5	nc	(nc-nc)	Male	7	5.3	131.7	(52.8-271.3)
Female	1	1.5	nc	(nc-nc)	Female	6	6.3	95.2	(34.8-207.2)
Hodgkin Lymphoma					Prostate				
Male	1	1.3	nc	(nc-nc)	Male	75	75.7	99.1	(77.9-124.2)
Female	2	1.1	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	4	4.8	nc	(nc-nc)
Male	8	7.2	110.9	(47.7-218.5)					

Larynx	Female	2	5.0	nc	(nc-nc)	Testis	Female	5	3.2	154.3	(49.7-360.1)
	Male	5	3.3	151.8	(48.9-354.4)		Male	2	2.0	nc	(nc-nc)
Leukemia	Female	2	0.9	nc	(nc-nc)	Thyroid					
	Male	3	5.5	nc	(nc-nc)		Male	1	1.6	nc	(nc-nc)
	Female	4	4.9	nc	(nc-nc)		Female	5	4.9	101.6	(32.7-237.1)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	1	3.4	nc	(nc-nc)						
	Female	4	1.4	nc	(nc-nc)		Female	13	13.9	93.6	(49.8-160.0)
Lung and Bronchus						All Sites / Types					
	Male	24	36.6	65.5	(42.0-97.5)		Male	200	245.6	81.4	(70.5-93.5)
	Female	26	32.8	79.4	(51.8-116.3)		Female	249	237.1	105.0	(92.4-118.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

97

#### Eastham

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	14	10.6	131.8	(72.0-221.1)	Male	7	4.6	153.5	(61.5-316.3)
Female	4	3.3	nc	(nc-nc)	Female	7	3.0	232.8	(93.3-479.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	1.6	nc	(nc-nc)	Male	7	1.4	493.7	(197.8-1017.3)
Female	2	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Cervix Uteri	Male	0	0.3	nc	(nc-nc)
	Female	36	31.0	116.0	(81.3-160.7)
Colon / Rectum	Female	0	1.2	nc	(nc-nc)
	Male	15	16.0	93.8	(52.4-154.7)
Esophagus	Female	20	13.1	152.8	(93.3-236.1)
	Male	3	2.4	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.6	nc	(nc-nc)
	Male	0	0.5	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.4	nc	(nc-nc)
	Male	2	3.7	nc	(nc-nc)
Larynx	Female	2	2.3	nc	(nc-nc)
	Male	2	1.7	nc	(nc-nc)
Leukemia	Female	0	0.4	nc	(nc-nc)
	Male	2	2.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	4	2.0	nc	(nc-nc)
	Male	2	1.7	nc	(nc-nc)
Lung and Bronchus	Female	0	0.6	nc	(nc-nc)
	Male	17	20.6	82.7	(48.1-132.3)
	Female	13	15.5	83.7	(44.5-143.1)

Oral Cavity & Pharynx	Male	6	4.7	128.8	(47.0-280.2)
	Female	3	3.9	nc	(nc-nc)
Ovary	Male	4	3.3	nc	(nc-nc)
	Female	2	1.5	nc	(nc-nc)
Pancreas	Female	2	3.2	nc	(nc-nc)
	Male	2	2.9	nc	(nc-nc)
Prostate	Female	1	2.8	nc	(nc-nc)
	Male	66	41.3	159.9	(123.6-203.4)
Stomach	Male	1	2.7	nc	(nc-nc)
	Female	0	1.3	nc	(nc-nc)
Testis	Male	1	0.7	nc	(nc-nc)
	Female	2	1.9	nc	(nc-nc)
Thyroid	Male	0	0.7	nc	(nc-nc)
	Female	2	1.9	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	8	6.3	126.1	(54.3-248.4)
	Male	162	132.9	121.9	(103.9-142.2)
All Sites / Types	Female	114	104.4	109.2	(90.1-131.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

98

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	16	16.8	95.4	(54.5-155.0)	Male	9	8.8	102.7	(46.8-194.9)
Female	6	6.5	92.1	(33.6-200.4)	Female	6	7.3	82.5	(30.1-179.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	3.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	5	2.9	173.1	(55.8-404.0)	Female	1	2.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)	Male	14	8.6	162.7	(88.9-273.0)
Female	65	68.0	95.6	(73.8-121.9)	Female	9	8.2	109.8	(50.1-208.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	3.2	nc	(nc-nc)	Male	6	6.4	93.1	(34.0-202.7)
Colon / Rectum					Female	2	3.3	nc	(nc-nc)
Male	27	25.9	104.3	(68.7-151.7)	Ovary				
Female	29	26.9	107.9	(72.2-154.9)	Female	2	7.0	nc	(nc-nc)
Esophagus					Pancreas				
Male	7	4.0	173.9	(69.7-358.4)	Male	11	4.8	228.5	(113.9-408.8)
Female	0	1.3	nc	(nc-nc)	Female	6	5.6	108.0	(39.4-235.0)
Hodgkin Lymphoma					Prostate				
Male	2	1.5	nc	(nc-nc)	Male	54	65.8	82.1	(61.6-107.1)
Female	2	1.3	nc	(nc-nc)					

Kidney & Renal Pelvis					Stomach				
Male	7	6.7	104.3	(41.8-215.0)	Male	5	4.4	113.2	(36.5-264.1)
Female	2	4.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
Larynx					Testis				
Male	0	3.0	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)					
Leukemia					Thyroid				
Male	5	5.2	95.7	(30.8-223.4)	Male	0	1.7	nc	(nc-nc)
Female	5	4.5	110.7	(35.7-258.4)	Female	5	5.6	89.4	(28.8-208.6)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	4	3.2	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)	Female	9	13.1	68.7	(31.3-130.4)
Lung and Bronchus					All Sites / Types				
Male	35	32.6	107.5	(74.8-149.5)	Male	220	223.0	98.6	(86.0-112.6)
Female	20	29.9	66.8	(40.8-103.2)	Female	197	222.4	88.6	(76.7-101.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

99  
Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	14	18.5	75.6	(41.3-126.9)	Male	18	10.6	169.3	(100.3-267.6)
Female	6	6.5	92.1	(33.6-200.5)	Female	6	8.8	68.4	(25.0-148.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	4.3	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)



Breast	Female	4	3.4	nc	(nc-nc)
	Male	0	0.6	nc	(nc-nc)
Cervix Uteri	Female	97	80.2	120.9	(98.1-147.5)
	Male				
Colon / Rectum	Female	10	4.0	247.9	(118.7-455.9)
	Male	27	29.3	92.3	(60.8-134.2)
Esophagus	Female	27	25.9	104.4	(68.8-151.9)
	Male	7	4.9	142.9	(57.3-294.5)
Hodgkin Lymphoma	Female	4	1.3	nc	(nc-nc)
	Male	2	2.0	nc	(nc-nc)
Kidney & Renal Pelvis	Female	4	1.7	nc	(nc-nc)
	Male	7	8.3	84.4	(33.8-173.9)
Larynx	Female	2	5.1	nc	(nc-nc)
	Male	1	3.7	nc	(nc-nc)
Leukemia	Female	0	0.9	nc	(nc-nc)
	Male	6	6.2	96.6	(35.3-210.4)
Liver and Intrahepatic Bile Ducts	Female	6	4.9	121.6	(44.4-264.7)
	Male	3	3.9	nc	(nc-nc)
Lung and Bronchus	Female	2	1.3	nc	(nc-nc)
	Male				

Non-Hodgkin Lymphoma	Female	2	2.0	nc	(nc-nc)
	Male	8	10.3	77.8	(33.5-153.3)
Oral Cavity & Pharynx	Female	4	8.6	nc	(nc-nc)
	Male	8	8.4	95.8	(41.2-188.8)
Ovary	Female	3	3.7	nc	(nc-nc)
	Male				
Pancreas	Female	5	8.0	62.2	(20.1-145.2)
	Male	4	5.5	nc	(nc-nc)
Prostate	Female	7	5.3	132.0	(52.9-272.1)
	Male	90	82.3	109.3	(87.9-134.4)
Stomach	Female	4	2.7	nc	(nc-nc)
	Male	6	5.0	121.0	(44.2-263.4)
Testis	Female				
	Male	3	3.5	nc	(nc-nc)
Thyroid	Female	6	7.4	81.3	(29.7-177.0)
	Male	2	2.3	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	10	15.7	63.8	(30.5-117.4)
	Male				
All Sites / Types					

Male	32	37.5	85.3	(58.3-120.4)
Female	27	31.2	86.7	(57.1-126.1)

Male	248	266.5	93.1	(81.8-105.4)
Female	255	245.2	104.0	(91.6-117.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

100  
Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	4.0	124.0	(40.0-289.3)	Male	1	2.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	8	16.1	49.6	(21.3-97.7)	Female	3	1.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.8	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Colon / Rectum					Female	1	0.8	nc	(nc-nc)
Male	5	6.3	79.1	(25.5-184.5)	Ovary				
Female	8	5.6	143.9	(62.0-283.6)	Female	3	1.6	nc	(nc-nc)
Esophagus					Pancreas				
Male	2	1.0	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	4	1.2	nc	(nc-nc)

Hodgkin Lymphoma					Prostate				
Male	0	0.4	nc	(nc-nc)	Male	18	17.4	103.4	(61.3-163.4)
Female	1	0.3	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	2	1.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Larynx					Testis				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	1.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	0.8	nc	(nc-nc)					
Female	1	0.3	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	8	8.1	98.5	(42.4-194.2)	Male	56	56.5	99.2	(74.9-128.8)
Female	6	6.7	89.4	(32.7-194.7)	Female	49	50.2	97.5	(72.2-129.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

101  
Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	2.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)

Brain and Other Nervous System	Female	0	0.7	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)
Breast	Female	0	0.3	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)
Cervix Uteri	Female	2	7.3	nc	(nc-nc)
	Female	1	0.3	nc	(nc-nc)
Colon / Rectum	Male	2	3.6	nc	(nc-nc)
	Female	1	2.7	nc	(nc-nc)
Esophagus	Male	0	0.5	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma	Male	0	0.1	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	0.9	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)
Larynx	Male	0	0.4	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)
Leukemia	Male	0	0.6	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					

Multiple Myeloma	Female	0	0.7	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma	Female	0	0.2	nc	(nc-nc)
	Male	0	1.1	nc	(nc-nc)
Oral Cavity & Pharynx	Female	0	0.8	nc	(nc-nc)
	Male	0	0.8	nc	(nc-nc)
Ovary	Female	1	0.4	nc	(nc-nc)
	Female	1	0.7	nc	(nc-nc)
Pancreas	Male	1	0.7	nc	(nc-nc)
	Female	1	0.6	nc	(nc-nc)
Prostate	Male	6	9.3	64.4	(23.5-140.2)
	Male	0	0.6	nc	(nc-nc)
Stomach	Female	0	0.3	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)
Testis	Male	0	0.2	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Thyroid	Female	1	0.5	nc	(nc-nc)
	Female	1	0.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					

Male	0	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	1	4.5	nc	(nc-nc)	Male	12	30.0	40.0	(20.7-69.9)
Female	1	3.3	nc	(nc-nc)	Female	12	23.4	51.3	(26.5-89.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

102  
Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	1.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	4	6.3	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
					Female	1	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	0	2.8	nc	(nc-nc)					
Female	2	2.4	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)

Esophagus						Pancreas					
Male	1	0.4	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)		Female	0	0.5	nc	(nc-nc)	
Hodgkin Lymphoma						Prostate					
Male	0	0.1	nc	(nc-nc)		Male	4	7.4	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)							
Kidney & Renal Pelvis						Stomach					
Male	0	0.7	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)	
Female	0	0.4	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)	
Larynx						Testis					
Male	0	0.3	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)							
Leukemia						Thyroid					
Male	2	0.5	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)	
Female	1	0.4	nc	(nc-nc)		Female	1	0.5	nc	(nc-nc)	
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
Male	0	0.3	nc	(nc-nc)							
Female	0	0.1	nc	(nc-nc)		Female	2	1.3	nc	(nc-nc)	
Lung and Bronchus						All Sites / Types					
Male	5	3.5	141.1	(45.5-329.3)		Male	17	24.2	70.3	(40.9-112.6)	
Female	3	2.8	nc	(nc-nc)		Female	20	20.3	98.4	(60.1-152.0)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	3.6	194.6	(78.0-401.0)
Female	0	1.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.7	nc	(nc-nc)
Female	6	0.6	1051.8	(384.1-2289.4)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	23	13.6	169.0	(107.1-253.6)
Cervix Uteri				
Female	3	0.6	nc	(nc-nc)
Colon / Rectum				
Male	5	5.6	89.4	(28.8-208.6)
Female	5	4.9	101.5	(32.7-236.8)
Esophagus				
Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	1.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Larynx				
Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	1.9	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)
Multiple Myeloma				
Male	2	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	1.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Ovary				
Female	0	1.4	nc	(nc-nc)
Pancreas				
Male	0	1.0	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)
Prostate				
Male	18	15.0	120.0	(71.1-189.6)
Stomach				
Male	2	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Testis				
Male	0	0.5	nc	(nc-nc)
Thyroid				

Male	1	1.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.7	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	3	7.2	nc	(nc-nc)	Male	50	49.2	101.7	(75.5-134.1)
Female	14	5.7	244.3	(133.4-409.9)	Female	65	43.0	151.1	(116.6-192.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

104  
Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	45	38.6	116.6	(85.1-156.0)	Male	12	19.4	61.8	(31.9-108.0)
Female	9	16.0	56.2	(25.6-106.6)	Female	10	17.2	58.0	(27.8-106.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	11	7.4	148.0	(73.8-264.9)	Male	4	5.3	nc	(nc-nc)
Female	3	6.9	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.1	nc	(nc-nc)	Male	23	19.3	119.0	(75.4-178.6)
Female	142	157.9	89.9	(75.7-106.0)	Female	20	19.9	100.7	(61.5-155.6)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	18	14.0	129.0	(76.4-203.8)
Female	6	7.5	79.9	(29.2-174.0)	Female	12	7.8	153.2	(79.0-267.6)



Colon / Rectum					Ovary				
Male	77	59.2	130.0	(102.6-162.5)					
Female	78	65.9	118.3	(93.5-147.7)	Female	22	16.4	134.4	(84.2-203.5)
Esophagus					Pancreas				
Male	13	9.1	142.6	(75.9-243.9)	Male	15	10.9	137.4	(76.8-226.6)
Female	2	3.2	nc	(nc-nc)	Female	18	13.7	131.1	(77.6-207.2)
Hodgkin Lymphoma					Prostate				
Male	5	3.5	142.1	(45.8-331.7)	Male	135	154.0	87.6	(73.5-103.7)
Female	2	3.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	16	14.9	107.4	(61.4-174.4)	Male	14	10.0	139.4	(76.1-233.9)
Female	20	11.1	179.5	(109.6-277.3)	Female	11	7.0	156.5	(78.0-280.0)
Larynx					Testis				
Male	9	6.7	134.1	(61.2-254.6)	Male	7	6.5	107.0	(42.9-220.5)
Female	1	2.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	11	11.9	92.5	(46.1-165.5)	Male	0	3.8	nc	(nc-nc)
Female	15	11.0	136.0	(76.1-224.3)	Female	14	13.1	107.2	(58.6-179.9)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	7	6.9	101.4	(40.6-209.0)					
Female	2	3.1	nc	(nc-nc)	Female	29	30.9	93.8	(62.8-134.7)
Lung and Bronchus					All Sites / Types				
Male	98	75.2	130.3	(105.8-158.8)	Male	561	511.8	109.6	(100.7-119.1)
Female	102	72.9	139.9	(114.1-169.9)	Female	557	531.6	104.8	(96.3-113.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



Male	2	3.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Leukemia				
Male	6	6.3	95.3	(34.8-207.4)
Female	6	5.7	104.5	(38.2-227.5)
Liver and Intrahepatic Bile Ducts				
Male	5	3.8	132.3	(42.6-308.7)
Female	0	1.7	nc	(nc-nc)
Lung and Bronchus				
Male	48	41.7	115.0	(84.8-152.5)
Female	34	38.8	87.6	(60.6-122.4)

Male	3	2.4	nc	(nc-nc)
Thyroid				
Male	1	1.8	nc	(nc-nc)
Female	3	5.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	16	16.1	99.5	(56.9-161.7)
All Sites / Types				
Male	298	279.2	106.7	(95.0-119.6)
Female	277	278.9	99.3	(88.0-111.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

106  
Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	95	102.1	93.1	(75.3-113.8)
Female	45	44.9	100.2	(73.1-134.0)
Brain and Other Nervous System				
Male	19	18.4	103.0	(62.0-160.9)
Female	23	18.1	127.2	(80.6-190.8)
Breast				
Male	4	2.9	nc	(nc-nc)
Female	341	410.9	83.0	(74.4-92.3)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	13	48.9	26.6	(14.1-45.5)
Female	25	43.5	57.5	(37.2-84.8)
Multiple Myeloma				
Male	16	13.9	115.1	(65.7-186.9)
Female	7	14.0	50.0	(20.0-103.1)
Non-Hodgkin Lymphoma				
Male	45	49.2	91.4	(66.7-122.4)
Female	56	54.0	103.6	(78.3-134.6)

Cervix Uteri						Oral Cavity & Pharynx					
	Male	44	35.3	124.7	(90.6-167.4)						
Female	25	18.1	138.2	(89.4-204.0)		Female	24	20.9	114.9	(73.6-171.0)	
Colon / Rectum						Ovary					
	Male	154	155.5	99.0	(84.0-116.0)						
	Female	159	187.8	84.6	(72.0-98.9)						
Esophagus						Pancreas					
	Male	28	23.6	118.9	(79.0-171.8)						
	Female	8	9.1	87.5	(37.7-172.5)						
Hodgkin Lymphoma						Prostate					
	Male	8	8.1	99.3	(42.7-195.6)						
	Female	7	7.8	90.3	(36.2-186.1)						
Kidney & Renal Pelvis						Stomach					
	Male	43	38.0	113.0	(81.8-152.3)						
	Female	34	29.9	113.6	(78.6-158.7)						
Larynx						Testis					
	Male	25	17.2	145.1	(93.9-214.2)						
	Female	11	5.2	212.0	(105.7-379.4)						
Leukemia						Thyroid					
	Male	36	30.7	117.3	(82.2-162.4)						
	Female	25	30.3	82.5	(53.4-121.8)						
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	26	17.6	147.4	(96.3-216.0)						
	Female	12	8.7	137.7	(71.1-240.6)						
Lung and Bronchus						All Sites / Types					
	Male	271	196.0	138.3	(122.3-155.8)						
	Female	174	199.1	87.4	(74.9-101.4)						
	Male	1346	1318.3	102.1	(96.7-107.7)						
	Female	1282	1427.8	89.8	(84.9-94.8)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

107  
Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	59	52.4	112.6	(85.7-145.2)	Male	40	23.5	170.0	(121.5-231.5)
Female	20	18.4	108.4	(66.2-167.4)	Female	30	17.4	172.4	(116.3-246.1)
Brain and Other Nervous System					Multiple Myeloma				
Male	11	8.3	133.0	(66.3-238.0)	Male	14	7.1	197.4	(107.8-331.2)
Female	13	7.1	182.6	(97.2-312.3)	Female	14	5.8	242.6	(132.5-407.1)
Breast					Non-Hodgkin Lymphoma				
Male	6	1.5	403.6	(147.4-878.6)	Male	21	23.8	88.3	(54.7-135.0)
Female	195	177.1	110.1	(95.2-126.7)	Female	28	21.9	127.6	(84.8-184.5)
Cervix Uteri					Oral Cavity & Pharynx				
Female	13	7.2	180.2	(95.8-308.1)	Male	11	17.6	62.5	(31.1-111.8)
Colon / Rectum					Female	6	8.8	68.2	(24.9-148.5)
Male	81	79.6	101.8	(80.9-126.5)	Ovary				
Female	72	74.8	96.3	(75.3-121.2)	Female	24	18.2	132.1	(84.6-196.5)
Esophagus					Pancreas				
Male	5	12.2	41.1	(13.3-96.0)	Male	13	14.7	88.6	(47.1-151.5)
Female	0	3.7	nc	(nc-nc)	Female	17	15.7	108.2	(63.0-173.2)
Hodgkin Lymphoma					Prostate				
Male	2	2.9	nc	(nc-nc)	Male	252	209.5	120.3	(105.9-136.1)
Female	3	2.6	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Male	14	19.1	73.2	(40.0-122.9)	Male	11	13.4	82.1	(40.9-146.8)
Female	14	12.7	110.3	(60.2-185.1)	Female	7	7.8	89.2	(35.8-183.9)
Larynx					Testis				
Male	11	8.9	124.0	(61.8-221.9)	Male	7	4.1	169.8	(68.0-349.9)
Female	4	2.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	14	14.5	96.3	(52.6-161.6)	Male	4	3.8	nc	(nc-nc)
Female	15	11.8	127.5	(71.3-210.4)	Female	10	11.5	87.2	(41.8-160.4)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	6	8.9	67.7	(24.7-147.4)					
Female	2	3.5	nc	(nc-nc)	Female	35	35.9	97.4	(67.8-135.5)
Lung and Bronchus					All Sites / Types				
Male	99	102.0	97.1	(78.9-118.2)	Male	729	670.7	108.7	(100.9-116.9)
Female	102	85.3	119.5	(97.5-145.1)	Female	669	593.5	112.7	(104.3-121.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

108  
Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	36	40.5	88.8	(62.2-123.0)	Male	11	19.9	55.2	(27.5-98.7)
Female	18	16.7	107.5	(63.7-169.9)	Female	11	16.9	65.0	(32.4-116.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	7.7	64.9	(20.9-151.5)	Male	4	5.5	nc	(nc-nc)
Female	10	7.1	140.9	(67.5-259.2)	Female	1	5.2	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)		Male	17	20.0	84.9	(49.4-136.0)
Female	143	157.1	91.0	(76.7-107.2)		Female	21	20.4	103.2	(63.8-157.7)
Cervix Uteri						Oral Cavity & Pharynx				
Female	9	7.1	126.3	(57.6-239.8)		Male	15	14.3	104.6	(58.5-172.5)
Colon / Rectum						Female	4	7.9	nc	(nc-nc)
Male	54	62.0	87.2	(65.5-113.7)		Ovary				
Female	65	69.8	93.2	(71.9-118.7)		Female	12	16.5	72.8	(37.6-127.2)
Esophagus						Pancreas				
Male	14	9.4	148.4	(81.1-249.1)		Male	11	11.4	96.2	(48.0-172.1)
Female	4	3.4	nc	(nc-nc)		Female	8	14.6	55.0	(23.7-108.3)
Hodgkin Lymphoma						Prostate				
Male	3	3.5	nc	(nc-nc)		Male	161	157.9	102.0	(86.8-119.0)
Female	3	3.2	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	12	10.5	113.9	(58.8-199.0)
Male	15	15.4	97.5	(54.5-160.9)		Female	10	7.6	132.4	(63.4-243.6)
Female	10	11.3	88.4	(42.3-162.6)		Testis				
Larynx						Male	9	6.2	146.3	(66.8-277.7)
Male	7	6.9	101.1	(40.5-208.4)		Thyroid				
Female	1	2.0	nc	(nc-nc)		Male	4	3.7	nc	(nc-nc)
Leukemia						Female	15	12.3	122.0	(68.2-201.2)
Male	10	12.5	79.9	(38.3-147.0)		Uteri Corpus and Uterus, NOS				
Female	5	11.7	42.8	(13.8-100.0)		Female	23	30.6	75.1	(47.6-112.6)
Liver and Intrahepatic Bile Ducts						All Sites / Types				
Male	6	7.2	83.9	(30.6-182.6)		Male	505	529.6	95.4	(87.2-104.0)
Female	3	3.3	nc	(nc-nc)						
Lung and Bronchus										
Male	75	78.2	95.9	(75.4-120.2)						

Female 58 74.2 78.1 (59.3-101.0)

Female 472 540.7 87.3 (79.6-95.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

109  
Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	1	1.3	nc	(nc-nc)					
Female	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				



Male	0	0.1	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Larynx					Testis				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.2	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	0	1.7	nc	(nc-nc)	Male	4	11.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	10	9.3	108.1	(51.7-198.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

110  
Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	16.0	56.2	(25.6-106.7)	Male	17	8.7	195.7	(113.9-313.3)
Female	9	5.8	155.4	(70.9-295.0)	Female	14	7.0	199.9	(109.2-335.5)

Brain and Other Nervous System						Multiple Myeloma				
Male	3	3.4	nc	(nc-nc)		Male	3	2.3	nc	(nc-nc)
Female	0	2.8	nc	(nc-nc)		Female	2	1.8	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)		Male	9	8.4	106.5	(48.6-202.2)
Female	86	65.8	130.8	(104.6-161.5)		Female	6	7.4	80.8	(29.5-175.9)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	6	6.7	89.7	(32.8-195.3)
Female	3	3.2	nc	(nc-nc)		Female	4	3.1	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	27	25.0	107.9	(71.1-157.0)						
Female	31	23.1	134.1	(91.1-190.4)		Female	8	6.6	120.9	(52.1-238.2)
Esophagus						Pancreas				
Male	6	4.1	146.7	(53.6-319.4)		Male	3	4.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)		Female	5	4.8	104.6	(33.7-244.0)
Hodgkin Lymphoma						Prostate				
Male	2	1.5	nc	(nc-nc)		Male	84	69.6	120.7	(96.2-149.4)
Female	2	1.2	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	6	6.9	87.6	(32.0-190.7)		Male	1	4.2	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)		Female	4	2.4	nc	(nc-nc)
Larynx						Testis				
Male	1	3.1	nc	(nc-nc)		Male	5	2.6	192.9	(62.2-450.2)
Female	0	0.8	nc	(nc-nc)						
Leukemia						Thyroid				
Male	9	5.1	174.9	(79.8-332.0)		Male	0	1.8	nc	(nc-nc)
Female	10	4.1	241.3	(115.5-443.8)		Female	5	5.6	89.9	(29.0-209.9)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	2	3.2	nc	(nc-nc)						

Female	3	1.1	nc	(nc-nc)	Female	12	13.0	92.5	(47.7-161.5)
Lung and Bronchus					All Sites / Types				
Male	27	32.3	83.6	(55.1-121.6)	Male	236	224.2	105.3	(92.3-119.6)
Female	31	27.5	112.6	(76.5-159.8)	Female	254	207.0	122.7	(108.1-138.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

111  
Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	64	65.7	97.5	(75.1-124.5)	Male	42	34.5	121.6	(87.7-164.4)
Female	32	25.7	124.4	(85.1-175.7)	Female	37	29.5	125.2	(88.2-172.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	12	13.3	90.5	(46.7-158.2)	Male	13	9.2	141.4	(75.2-241.8)
Female	11	11.6	94.5	(47.1-169.0)	Female	8	8.0	100.1	(43.1-197.3)
Breast					Non-Hodgkin Lymphoma				
Male	1	2.0	nc	(nc-nc)	Male	32	33.9	94.3	(64.5-133.2)
Female	294	267.9	109.7	(97.5-123.0)	Female	43	32.2	133.3	(96.5-179.6)
Cervix Uteri					Oral Cavity & Pharynx				
Female	14	13.1	107.2	(58.6-179.9)	Male	27	25.5	105.7	(69.7-153.8)
Colon / Rectum					Female	15	13.1	114.6	(64.1-189.1)
Male	111	101.7	109.1	(89.8-131.4)	Ovary				
Female	124	105.2	117.8	(98.0-140.5)	Female	26	27.6	94.3	(61.6-138.2)
Esophagus					Pancreas				

	Male	13	16.1	80.9	(43.0-138.3)
	Female	3	5.2	nc	(nc-nc)
Hodgkin Lymphoma					
	Male	9	6.3	143.9	(65.7-273.2)
	Female	2	5.5	nc	(nc-nc)
Kidney & Renal Pelvis					
	Male	30	26.6	112.9	(76.1-161.2)
	Female	18	18.2	98.6	(58.4-155.9)
Larynx					
	Male	9	12.0	75.3	(34.3-142.9)
	Female	1	3.2	nc	(nc-nc)
Leukemia					
	Male	23	20.6	111.4	(70.6-167.2)
	Female	25	18.2	137.3	(88.8-202.7)
Liver and Intrahepatic Bile Ducts					
	Male	15	12.3	121.9	(68.2-201.0)
	Female	8	5.0	160.3	(69.0-315.8)
Lung and Bronchus					
	Male	110	129.2	85.2	(70.0-102.6)
	Female	111	117.0	94.8	(78.0-114.2)

	Male	15	18.9	79.4	(44.4-130.9)
	Female	25	21.8	114.5	(74.1-169.0)
Prostate					
	Male	247	271.2	91.1	(80.1-103.2)
Stomach					
	Male	20	17.3	115.7	(70.6-178.7)
	Female	10	11.3	88.6	(42.4-162.9)
Testis					
	Male	15	11.6	128.9	(72.1-212.6)
Thyroid					
	Male	7	7.0	100.6	(40.3-207.2)
	Female	27	23.1	116.8	(76.9-169.9)
Uteri Corpus and Uterus, NOS					
	Female	60	52.5	114.4	(87.3-147.2)
All Sites / Types					
	Male	875	893.0	98.0	(91.6-104.7)
	Female	959	879.7	109.0	(102.2-116.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	18	20.3	88.5	(52.4-139.8)		Male	15	12.3	121.9	(68.2-201.1)
Female	6	7.6	79.0	(28.8-172.0)		Female	16	10.7	149.5	(85.4-242.7)
Brain and Other Nervous System						Multiple Myeloma				
Male	5	5.2	96.7	(31.2-225.6)		Male	3	3.0	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)		Female	2	2.4	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.7	nc	(nc-nc)		Male	8	11.8	67.7	(29.1-133.4)
Female	106	94.4	112.3	(91.9-135.8)		Female	7	10.3	68.0	(27.2-140.0)
Cervix Uteri						Oral Cavity & Pharynx				
Female	6	5.2	116.1	(42.4-252.6)		Male	9	9.3	97.0	(44.3-184.2)
Colon / Rectum						Female	2	4.3	nc	(nc-nc)
Male	36	32.2	111.7	(78.2-154.7)		Ovary				
Female	29	30.4	95.4	(63.9-137.0)		Female	14	9.4	148.3	(81.0-248.9)
Esophagus						Pancreas				
Male	4	5.3	nc	(nc-nc)		Male	5	6.1	82.4	(26.6-192.3)
Female	4	1.5	nc	(nc-nc)		Female	6	6.2	96.6	(35.3-210.2)
Hodgkin Lymphoma						Prostate				
Male	1	2.5	nc	(nc-nc)		Male	90	88.5	101.7	(81.8-125.0)
Female	0	2.1	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	4	5.5	nc	(nc-nc)
Male	7	9.3	74.9	(30.0-154.4)		Female	1	3.2	nc	(nc-nc)
Female	2	6.0	nc	(nc-nc)		Testis				
Larynx						Male	6	4.8	125.6	(45.9-273.4)
Male	2	4.1	nc	(nc-nc)		Thyroid				
Female	2	1.1	nc	(nc-nc)		Male	3	2.8	nc	(nc-nc)
Leukemia										
Male	4	7.4	nc	(nc-nc)						

Female	7	6.2	113.7	(45.6-234.4)
Liver and Intrahepatic Bile Ducts				
Male	2	4.3	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	37	41.1	90.0	(63.3-124.0)
Female	29	36.1	80.3	(53.8-115.3)

Female	5	9.4	53.1	(17.1-124.0)
Uteri Corpus and Uterus, NOS				
Female	15	17.9	83.9	(46.9-138.4)
All Sites / Types				
Male	276	295.8	93.3	(82.6-105.0)
Female	284	289.9	98.0	(86.9-110.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

113  
Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	11	7.7	142.0	(70.8-254.2)
Female	1	2.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	1.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	31	33.5	92.6	(62.9-131.5)
Cervix Uteri				
Female	2	1.7	nc	(nc-nc)
Colon / Rectum				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	4.5	109.9	(35.4-256.5)
Female	5	3.6	140.3	(45.2-327.5)
Multiple Myeloma				
Male	0	1.1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	5	4.3	115.1	(37.1-268.5)
Female	3	3.4	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	3.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Ovary				

Esophagus	Male	12	12.3	97.7	(50.4-170.6)	Pancreas				
	Female	6	10.2	58.9	(21.5-128.3)		Female	4	3.3	nc (nc-nc)
Hodgkin Lymphoma	Male	1	2.1	nc	(nc-nc)	Prostate	Male	2	2.3	nc (nc-nc)
	Female	0	0.5	nc	(nc-nc)		Female	2	2.1	nc (nc-nc)
Kidney & Renal Pelvis	Male	0	0.8	nc	(nc-nc)	Stomach	Male	35	34.5	101.5 (70.7-141.1)
	Female	1	0.6	nc	(nc-nc)		Female	1	1.0	nc (nc-nc)
Larynx	Male	2	3.6	nc	(nc-nc)	Testis	Male	1	2.1	nc (nc-nc)
	Female	1	2.1	nc	(nc-nc)		Female	1	1.0	nc (nc-nc)
Leukemia	Male	2	1.6	nc	(nc-nc)	Thyroid	Male	3	1.4	nc (nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	0	1.0	nc (nc-nc)
Liver and Intrahepatic Bile Ducts	Male	2	2.6	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Female	4	3.0	nc (nc-nc)
	Female	2	1.9	nc	(nc-nc)		Female	4	6.5	nc (nc-nc)
Lung and Bronchus	Male	1	1.7	nc	(nc-nc)	All Sites / Types	Male	106	112.0	94.6 (77.4-114.4)
	Female	0	0.5	nc	(nc-nc)		Female	82	99.6	82.3 (65.5-102.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;